A Pilot Randomized Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the safety of serial intradermal vaccinations of a DNA vaccine encoding PAP, with GM-CSF as an adjuvant, in patients with non-metastatic castrate-resistant prostate cancer.
While receiving vaccine treatment
Douglas McNeel, MD
University of Wisconsin, Madison
United States: Food and Drug Administration
|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center||Madison, Wisconsin 53792-6164|